$2.33 Billion is the total value of SABBY MANAGEMENT, LLC's 252 reported holdings in Q2 2014. The portfolio turnover from Q1 2014 to Q2 2014 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| WY | New | WEYERHAEUSER CO | $64,558,000 | – | 1,950,977 | +100.0% | 2.77% | – |
| New | ISHARES RUSSELL 2000put | $49,496,000 | – | 4,166 | +100.0% | 2.12% | – | |
| New | WEYERHAEUSER COput | $44,672,000 | – | 13,500 | +100.0% | 1.92% | – | |
| New | CELGENE CORPcall | $28,066,000 | – | 3,268 | +100.0% | 1.20% | – | |
| New | TESLA MOTORS INCput | $23,886,000 | – | 995 | +100.0% | 1.02% | – | |
| New | ACTAVIS PLCcall | $17,286,000 | – | 775 | +100.0% | 0.74% | – | |
| New | ACTAVIS PLCput | $16,729,000 | – | 750 | +100.0% | 0.72% | – | |
| New | TRI POINTE HOMES INCput | $12,397,000 | – | 7,886 | +100.0% | 0.53% | – | |
| New | CBS OUTDOOR AMERICAS INCput | $9,321,000 | – | 1,500 | +100.0% | 0.40% | – | |
| New | AEGERION PHARMACEUTICALS INCcall | $8,664,000 | – | 2,700 | +100.0% | 0.37% | – | |
| New | ASTRAZENECA PLCcall | $8,561,000 | – | 1,152 | +100.0% | 0.37% | – | |
| B108PS | New | ACTAVIS PLC | $7,445,000 | – | 33,376 | +100.0% | 0.32% | – |
| New | ASTRAZENECA PLCput | $7,372,000 | – | 992 | +100.0% | 0.32% | – | |
| New | ALNYLAM PHARMACEUTICALS INCput | $6,797,000 | – | 1,076 | +100.0% | 0.29% | – | |
| New | WELLPOINT INCcall | $5,940,000 | – | 552 | +100.0% | 0.26% | – | |
| New | GW PHARMACEUTICALS PLCcall | $5,204,000 | – | 485 | +100.0% | 0.22% | – | |
| TSLA | New | TESLA MOTORS INC | $5,175,000 | – | 21,557 | +100.0% | 0.22% | – |
| QPAC | New | QUINPARIO ACQUISITION CORP | $4,844,000 | – | 461,756 | +100.0% | 0.21% | – |
| New | NPS PHARMACEUTICALS INCput | $4,346,000 | – | 1,315 | +100.0% | 0.19% | – | |
| CYTX | New | CYTORI THERAPEUTICS INC | $4,292,000 | – | 1,795,963 | +100.0% | 0.18% | – |
| AZN | New | ASTRAZENECA PLCadr | $4,182,000 | – | 56,275 | +100.0% | 0.18% | – |
| New | UNITEDHEALTH GROUP INCcall | $3,679,000 | – | 450 | +100.0% | 0.16% | – | |
| OGXI | New | ONCOGENEX PHARMACEUTICAL INC | $3,441,000 | – | 922,562 | +100.0% | 0.15% | – |
| CBS | New | CBS CORP-CLASS B NON VOTINGcl b | $2,989,000 | – | 48,100 | +100.0% | 0.13% | – |
| OXGN | New | OXIGENE INC | $2,879,000 | – | 1,111,798 | +100.0% | 0.12% | – |
| RIBT | New | RICEBRAN TECHNOLOGIES | $2,857,000 | – | 541,044 | +100.0% | 0.12% | – |
| New | VANDA PHARMACEUTICALS INCcall | $2,751,000 | – | 1,700 | +100.0% | 0.12% | – | |
| New | BLUEBIRD BIO INCcall | $2,661,000 | – | 690 | +100.0% | 0.11% | – | |
| LPCN | New | LIPOCINE INC | $2,542,000 | – | 416,700 | +100.0% | 0.11% | – |
| ARWR | New | ARROWHEAD RESEARCH CORP | $2,466,000 | – | 172,353 | +100.0% | 0.11% | – |
| AVNR | New | AVANIR PHARMACEUTICALS INCcl a | $2,448,000 | – | 434,000 | +100.0% | 0.10% | – |
| XNCR | New | XENCOR INC | $2,437,000 | – | 209,686 | +100.0% | 0.10% | – |
| RVNC | New | REVANCE THERAPEUTICS INC | $2,285,000 | – | 67,200 | +100.0% | 0.10% | – |
| VNDA | New | VANDA PHARMACEUTICALS INC | $2,103,000 | – | 130,000 | +100.0% | 0.09% | – |
| New | GW PHARMACEUTICALS PLCput | $2,017,000 | – | 188 | +100.0% | 0.09% | – | |
| New | RETROPHIN INCcall | $1,961,000 | – | 1,670 | +100.0% | 0.08% | – | |
| New | NOVO NORDISK A/Sput | $1,958,000 | – | 424 | +100.0% | 0.08% | – | |
| EBIO | New | ELEVEN BIOTHERAPEUTICS INC | $1,898,000 | – | 143,974 | +100.0% | 0.08% | – |
| MEIP | New | MEI PHARMA INC | $1,712,000 | – | 270,000 | +100.0% | 0.07% | – |
| New | SALIX PHARMACEUTICALScall | $1,690,000 | – | 137 | +100.0% | 0.07% | – | |
| HRTX | New | HERON THERAPEUTICS INC | $1,667,000 | – | 135,281 | +100.0% | 0.07% | – |
| New | INTERCEPT PHARMACEUTICALS INCcall | $1,609,000 | – | 68 | +100.0% | 0.07% | – | |
| New | TESARO INCput | $1,556,000 | – | 500 | +100.0% | 0.07% | – | |
| New | TONIX PHARMACEUTICALS HOLDING CORPput | $1,435,000 | – | 1,000 | +100.0% | 0.06% | – | |
| BMY | New | BRISTOL-MYERS SQUIBB CO | $1,453,000 | – | 29,949 | +100.0% | 0.06% | – |
| NLNK | New | NEWLINK GENETICS CORP | $1,224,000 | – | 46,098 | +100.0% | 0.05% | – |
| IPCI | New | INTELLIPHARMACEUTICS INTERNAINC COM | $1,196,000 | – | 314,000 | +100.0% | 0.05% | – |
| New | GERON CORPcall | $1,172,000 | – | 3,651 | +100.0% | 0.05% | – | |
| New | KYTHERA BIOPHARMACEUTICALS INCcall | $1,151,000 | – | 300 | +100.0% | 0.05% | – | |
| J106OPTLDIV | New | CBS OUTDOOR AMERICAS INC | $1,148,000 | – | 35,142 | +100.0% | 0.05% | – |
| RPRX | New | REPROS THERAPEUTICS INC | $1,141,000 | – | 65,978 | +100.0% | 0.05% | – |
| ASPX | New | AUSPEX PHARMACEUTICALS INC | $1,114,000 | – | 50,000 | +100.0% | 0.05% | – |
| CORI | New | CORIUM INTERNATIONAL INC | $1,031,000 | – | 132,722 | +100.0% | 0.04% | – |
| BCRX | New | BIOCRYST PHARMACEUTICALS INC | $994,000 | – | 77,987 | +100.0% | 0.04% | – |
| P103PS | New | NPS PHARMACEUTICALS INC | $993,000 | – | 30,058 | +100.0% | 0.04% | – |
| OHRP | New | OHR PHARMACEUTICAL INC | $940,000 | – | 98,800 | +100.0% | 0.04% | – |
| RGDO | New | REGADO BIOSCIENCE INC | $889,000 | – | 131,000 | +100.0% | 0.04% | – |
| CLVS | New | CLOVIS ONCOLOGY INC | $828,000 | – | 20,000 | +100.0% | 0.04% | – |
| ARIA | New | ARIAD PHARMACEUTICALS INC | $808,000 | – | 126,884 | +100.0% | 0.04% | – |
| New | VIVUS INCcall | $795,000 | – | 1,495 | +100.0% | 0.03% | – | |
| New | OHR PHARMACEUTICAL INCcall | $745,000 | – | 783 | +100.0% | 0.03% | – | |
| ALNY | New | ALNYLAM PHARMACEUTICALS INC | $758,000 | – | 12,000 | +100.0% | 0.03% | – |
| New | ALNYLAM PHARMACEUTICALS INCcall | $600,000 | – | 95 | +100.0% | 0.03% | – | |
| PEIX | New | PACIFIC ETHANOL INC | $604,000 | – | 39,500 | +100.0% | 0.03% | – |
| NBS | New | NEOSTEM INC | $542,000 | – | 83,167 | +100.0% | 0.02% | – |
| New | ALIMERA SCIENCES INCcall | $533,000 | – | 891 | +100.0% | 0.02% | – | |
| BIOD | New | BIODEL INC | $520,000 | – | 240,600 | +100.0% | 0.02% | – |
| New | SYNERGY PHARMACEUTICALS - CW16*w | $515,000 | – | 389,982 | +100.0% | 0.02% | – | |
| New | OHR PHARMACEUTICAL INCput | $487,000 | – | 512 | +100.0% | 0.02% | – | |
| New | EPIZYME INCcall | $479,000 | – | 154 | +100.0% | 0.02% | – | |
| GEVO | New | GEVO INC | $478,000 | – | 555,456 | +100.0% | 0.02% | – |
| New | ALCOBRA LTDput | $344,000 | – | 199 | +100.0% | 0.02% | – | |
| FOLD | New | AMICUS THERAPEUTICS INC | $334,000 | – | 100,000 | +100.0% | 0.01% | – |
| TPH | New | TRI POINTE HOMES INC | $290,000 | – | 18,438 | +100.0% | 0.01% | – |
| HART | New | HARVARD APPARATUS REGENERATION | $290,000 | – | 27,730 | +100.0% | 0.01% | – |
| MDCO | New | MEDICINES CO | $231,000 | – | 7,948 | +100.0% | 0.01% | – |
| NURO | New | NEUROMETRIX INC | $226,000 | – | 116,400 | +100.0% | 0.01% | – |
| PRTA | New | PROTHENA CORP PLC | $221,000 | – | 9,800 | +100.0% | 0.01% | – |
| New | ARENA PHARMACEUTICALS INCcall | $179,000 | – | 306 | +100.0% | 0.01% | – | |
| New | EDAP TMS SAput | $162,000 | – | 326 | +100.0% | 0.01% | – | |
| QPACW | New | QUINPARIO ACQUISITION - CW18*w | $82,000 | – | 60,400 | +100.0% | 0.00% | – |
| New | OXIGENE INCcall | $71,000 | – | 275 | +100.0% | 0.00% | – | |
| ADXS | New | ADVAXIS INC | $60,000 | – | 19,000 | +100.0% | 0.00% | – |
| New | GERON CORPput | $34,000 | – | 107 | +100.0% | 0.00% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SPDR S&P 500 ETF TRUST UNIT | 37 | Q3 2023 | 49.1% |
| ISHARES TR | 35 | Q3 2023 | 52.2% |
| SPDR S&P BIOTECHNOLOGY | 32 | Q3 2022 | 12.8% |
| AMARIN CORP PLC | 30 | Q4 2021 | 2.0% |
| BIOGEN INC | 24 | Q1 2021 | 26.2% |
| SAREPTA THERAPEUTICS INC | 24 | Q3 2020 | 4.6% |
| BIOGEN INC | 23 | Q1 2021 | 13.7% |
| SAREPTA THERAPEUTICS INC | 22 | Q3 2020 | 6.2% |
| BRAINSTORM CELL THERAPEUTICS INC | 21 | Q3 2023 | 1.6% |
| VERTEX PHARMACEUTICALS INC | 20 | Q1 2018 | 12.6% |
View SABBY MANAGEMENT, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| AGM GROUP HOLDINGS, INC. | January 10, 2023 | 627,936 | 2.6% |
| Bit Digital, Inc | January 10, 2023 | 3,166,917 | 3.8% |
| Cingulate Inc. | January 10, 2023 | 10 | 5.0% |
| Context Therapeutics Inc. | January 10, 2023 | 796,706 | 5.0% |
| HeartBeam, Inc. | January 10, 2023 | 271,788 | 3.4% |
| PharmaCyte Biotech, Inc. | January 10, 2023 | 934,456 | 5.0% |
| Rebus Holdings, Inc.Sold out | January 10, 2023 | 0 | 0.0% |
| TANTECH HOLDINGS LTD | January 10, 2023 | 41,500 | 0.6% |
| Quanergy Systems, Inc. | January 04, 2023 | 936,905 | 5.8% |
| TuanChe Ltd | January 04, 2023 | 2,384,713 | 10.0% |
View SABBY MANAGEMENT, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-01-04 |
| SC 13G | 2024-01-04 |
| SC 13G | 2024-01-04 |
| SC 13G | 2024-01-04 |
| SC 13G | 2024-01-04 |
| SC 13G | 2024-01-03 |
| SC 13G | 2024-01-03 |
| SC 13G | 2024-01-03 |
View SABBY MANAGEMENT, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.